Hubert Pascale, Bousarghin Latifa, Greimers Roland, Franzen-Detrooz Elizabeth, Boniver Jacques, Delvenne Philippe
Department of Pathology, CRCE, B35, University of Liege, CHU Sart Tilman, Liege, Belgium.
Exp Dermatol. 2005 Jun;14(6):469-77. doi: 10.1111/j.0906-6705.2005.00299.x.
Langerhans' cells (LCs) are a subset of immature dendritic cells (DCs) and play a key role in the initiation and regulation of immune responses. Functional studies of these cells have been hampered by difficulties in generating a large number of LCs in vitro. We describe a new method to efficiently generate immature DCs exhibiting morphological, immunohistochemical, and ultrastructural features of LCs (CD1a+, Birbeck Granules+, CD207+, E-cadherin+, cutaneous lymphocyte-associated antigen+, and CCR6+) from a limited number of CD34+ cord blood progenitors. This method is based on a two-step procedure consisting of an amplification phase followed by a terminal differentiation induction. The amplification step is initiated with a combination of hematopoietic growth factors (thrombopoietin/stem cell factor/fetal liver tyrosine kinase-3 ligand), cytokines (granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-alpha, and interleukin-4), and 5 ng/ml of transforming growth factor (TGF)-beta1. The differentiation is induced by increasing the concentration of TGF-beta1 to 12.5 ng/ml. These culture conditions were efficient for generating a large number of immature LCs (8.74 x 10(6) +/- 3.2) from 15 x 10(4) CD34+ progenitor cells. In addition, these LCs were shown to be able to infiltrate an in vitro reconstructed epithelium. Because LCs play an important role in the mucosal immunity, this technique could be useful to study their interactions with epithelial pathogenic agents and to perform pharmacological, toxicological, and clinical research.
朗格汉斯细胞(LCs)是未成熟树突状细胞(DCs)的一个亚群,在免疫反应的启动和调节中起关键作用。由于难以在体外大量生成这些细胞,对其功能的研究受到了阻碍。我们描述了一种新方法,可从有限数量的CD34+脐带血祖细胞高效生成表现出LCs形态、免疫组织化学和超微结构特征(CD1a+、伯贝克颗粒+、CD207+、E-钙黏蛋白+、皮肤淋巴细胞相关抗原+和CCR6+)的未成熟DCs。该方法基于两步程序,包括扩增阶段和终末分化诱导。扩增步骤起始于造血生长因子(血小板生成素/干细胞因子/胎儿肝酪氨酸激酶-3配体)、细胞因子(粒细胞-巨噬细胞集落刺激因子、肿瘤坏死因子-α和白细胞介素-4)以及5 ng/ml转化生长因子(TGF)-β1的组合应用。通过将TGF-β1浓度增加至12.5 ng/ml来诱导分化。这些培养条件能够从15×10⁴个CD34+祖细胞高效生成大量未成熟LCs(8.74×10⁶±3.2)。此外,这些LCs能够浸润体外重建的上皮组织。由于LCs在黏膜免疫中起重要作用,该技术可能有助于研究它们与上皮病原体的相互作用,并用于进行药理学、毒理学和临床研究。